Search Results - sangeeta+ray

11 Results

Sort By:

Long-Circulating PSMA-Targeted Phototheranostic Agent

Unmet NeedProstate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. A promising precision cancer treatment known as photodynamic therapy (PDT) offers a way to selectively target prostate cancer cells for destruction. Prostate PDT uses a ligand to attach a light-sensitizing agent known as porphyrin...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ronnie Mease, Ying Chen, Sangeeta Ray, Juan Chen, Marta Overchuk, Gang Zheng, Kara Harmatys

Keywords(s): Cancers, Disease Indication, Imaging and Sensing Systems, In Vivo Medical Imaging, Prostate Cancer, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Clinical and Disease Specializations > Men's Health, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Therapeutic Modalities > Targets

PSMA-Targeted PAMAM Dendrimers for Specific Delivery of Imaging, Contrast and Therapeutic Agents

Unmet NeedAccording to The American Cancer Society, approximately 1 in 9 men will be diagnosed with prostate cancer in their lifetime, with 174,650 new cases diagnosed yearly in the US. As prostate cancer is the second leading cause of cancer death in American men, early detection is important for adequate treatment. The most common method of detecting...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Wojciech Lesniak, Srikanth Boinapally, Sangeeta Ray, Catherine Foss

Keywords(s): Cancers, Dendrimers, Disease Indication, Drug Delivery Vehicle, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Prostate Cancer, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Medical Devices > Imaging

Competitive PSMA Binding Agents for Reduction of Non-target Organ Uptake of Radiolabeled PSMA Inhibitors for PSMA Positive Tumor Imaging and Radiopharmaceutical Therapy

Unmet NeedProstate cancer is the second leading cause of cancer related death in American men and it is estimated that approximately 164,690 new cases will be diagnosed in 2018. Elevated prostate-specific membrane antigen (PSMA) serves as a biomarker for prostate cancer and as well as primary clear cell renal carcinoma (ccRCC). However, PSMA is also...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ronnie Mease, Sangeeta Ray, Il Minn

Keywords(s): Cancers, Combination, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Prostate Cancer, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Prostate-specific Membrane Antigen Targeted Plasmon-enhanced Raman Spectroscopy Reporters for Molecular Imaging of Prostate Cancer

Unmet Need:Non-invasive assessment of tumor burden and cancer-selective treatment in prostate cancer. This approach is will allow visualization in real-time of the distribution and action of therapeutic agents in vivo by transducing the presence of PSMA at the tissue level to characteristic Raman spectral patterns. This nanoplex platform, therefore,...

Published: 9/26/2024 | Inventor(s): Ishan Barman, Ming Li, Martin Pomper, Sangeeta Ray

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Non-novel, Predicted Novelty, Prostate Cancer, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Medical Devices, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

A Preclinical Comparative Study of 68Ga-Labeled DOTA, NOTA and HBED-CC Chelated PSMA-targeted Radiotracers

Prostate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. Therapy for locally advanced disease remains contentious and an increasing number of disparate options are available. We have been engaged in the development of new, high-sensitivity, low molecular weight imaging agents for prostate cancer...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Sangeeta Ray, Ronnie Mease

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Prostate Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Imaging

Radiolabeled Triazole Conjugated Ureas (YC-88)

Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate tumors, particularly in castrate-resistant, advanced and metastatic disease. PSMA is also expressed in neovascular endothelium of most solid tumors, such as lung, colon, pancreatic, renal carcinoma and skin melanoma, but not in normal...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ronnie Mease, Ying Chen, Sangeeta Ray, Xing Yang

Keywords(s): Antagonists/Inhibitors, Cancers, Discovery/Research Tools, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Labels/Markers, Novel, Predicted Novelty, Research Reagent, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics > Diagnostic Imaging

Salicylic Acid-based Polymeric CEST Contrast Agents for Molecular Imaging of Prostate-specific Membrane Antigen

We have discovered that a salicylic acid (SA) analog when grafted on a polymeric platform is able to produce significantly enhanced contrast in MR images detectable through chemical exchange saturation transfer (CEST). That SA modified polymeric platform (SA PolyCEST), has been further modified with Glu-Lysine urea, an inhibitor of Prostate-specific...

Published: 9/26/2024 | Inventor(s): Xing Yang, Michael Mcmahon, Sangeeta Ray, Xiaolei Song, Martin Pomper

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI), Prostate Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Clinical and Disease Specializations > Oncology

New Scaffolds and Multifunctional Intermediates for Imaging PSMA

The prostate-specific membrane antigen (PSMA) is increasingly recognized as an important target for cancer imaging and therapy. Current PSMA inhibitors based on a urea scaffold have shown good results for imaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) in human subjects. The urea scaffold has...

Published: 9/26/2024 | Inventor(s): Martin Pomper, Ying Chen, Sangeeta Ray, Ronnie Mease, Xing Yang, Georgio Attardo

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Positron Emission Tomography (PET), Prostate Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Clinical and Disease Specializations > Oncology

Azole Heterocycles for MRI Contrast and pH Sensing

C12402: Novel Class of Organic MRI Contrast AgentsNovelty: Group of organic compounds as magnetic resonance imaging (MRI) contrast agents for detecting pH changes in vivo.Value Proposition: The most commonly used MRI contrast agents contain the metal gadolinium which been associated with Nephrogenic Systemic Fibrosis. Therefore, organic agents serve...

Published: 9/26/2024 | Inventor(s): Sangeeta Ray, Martin Pomper, Xing Yang, Xiaolei Song, Michael Mcmahon

Keywords(s): Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI)

Category(s): Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices

Salicylic Acid and Its Analogs for MRI Contrast

C12400: Salicylic Acid and its Analogs as MRI Contrast AgentsNovelty: New use of salicylic acid and its analogues as improved contrast agents for magnetic resonance imaging (MRI).Value Proposition: Currently used MRI contrast agents either have toxic effects or have certain sensitivity drawbacks, especially due to a small chemical shift difference between...

Published: 9/26/2024 | Inventor(s): Sangeeta Ray, Xing Yang, Martin Pomper, Xiaolei Song, Michael Mcmahon

Keywords(s): Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI), Non-novel, Predicted Novelty, Repurposed

Category(s): Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Technology Classifications > Diagnostics > Diagnostic Imaging

1 2